4 min read
Metabolic Comorbidity in Preclinical Stroke, Pain and Wound Models
By: MD Biosciences on Nov 17, 2026, 9:00:01 AM
Among US adults aged 60 and older, metabolic syndrome prevalence reached roughly 62 percent by 2021 to 2023 in a national survey analysis published in the Journal of the American Medical Association. This is the age group in which stroke, neurodegenerative disease, diabetic neuropathy and chronic wounds are most common. A patient enrolling in a trial for any of those conditions is more likely than not to have metabolic disease as well. A preclinical study that evaluates a candidate in young, lean, metabolically normal animals therefore evaluates it in a population the trial will not enroll.
Combining therapeutic areas in a preclinical setting means building that comorbidity into the study, so that the animal has the metabolic disease present in the patient while the endpoint remains the one the program is developing toward. MD Biosciences runs the metabolic models and the disease models with which they are combined in the same laboratory.
GLP-1 Receptor Agonists and the Comorbid Population
GLP-1 receptor agonists as treatment of the comorbid population
Patients with metabolic disease are increasingly treated. Semaglutide reduced cardiovascular events in people with obesity and established cardiovascular disease in the SELECT trial, a population that included patients with prior stroke, and reduced nonfatal stroke in people with type II diabetes in SUSTAIN-6. In April 2026 the FDA approved orforglipron, the first oral small molecule in the class, which expands the population likely to be receiving one of these agents. The comorbid patient enrolled in a stroke, neuropathy or wound care trial is therefore increasingly a treated comorbid patient, whose glucose handling has already been modified by therapy.
GLP-1 receptor agonists as candidates for the comorbid conditions
The class itself is being pursued for the comorbid conditions. GLP-1 receptor agonists are under investigation for secondary stroke prevention, where the published evidence to date favors their use, and as acute stroke treatments. In the phase II TEXAIS trial, exenatide given within nine hours of onset reduced hyperglycemic events but did not improve neurological impairment at seven days, and semaglutide is being studied closer to reperfusion. Programs taking a metabolic mechanism into a neurological or wound healing indication must demonstrate a disease effect in an animal that carries the metabolic condition for which the drug was developed.
Preclinical Recommendations on Comorbidity
The Stroke Therapy Academic Industry Roundtable recommendations were updated in the journal Stroke in 2009. They state that after initial evaluation in young healthy male animals, candidate therapies should be tested in females, aged animals, and animals with comorbid conditions such as hypertension, diabetes and hypercholesterolemia. MD Biosciences accounts for age, sex and comorbidity in the design of its stroke, pain and wound studies.
How the Combinations Are Built
Metabolic syndrome and stroke
The focal stroke model is middle cerebral artery occlusion, which produces focal ischemia in the striatum and cortex with damage similar to that seen in human stroke. It runs in SD rats and C57Bl/6 mice, with permanent or transient occlusion before reperfusion, and laser Doppler flowmetry confirms the fall and return of cerebral blood flow during surgery. Infarct size is quantified by TTC staining alongside clinical assessment, cylinder, grip strength and forelimb placing tests. Because it runs in both species, it can be combined with any of the three metabolic inductions described below, and age, sex and metabolic comorbidity arms are designed around the population a sponsor expects. The model has been characterized across age and sex. Grip strength recovery varies with age and sex, with young males recovering fastest, and infarct size at seven days is larger in young females than in young males or aged animals of either sex.
Metabolic syndrome and neuropathic pain
Streptozotocin produces type I diabetes in SD rats and C57Bl/6 mice within days, and high fat diet produces insulin resistance in C57Bl/6 mice over 11 to 16 weeks. The Zucker Diabetic Fatty rat develops obese type II diabetes spontaneously over 13 weeks. In each, the pain endpoints are measured in the metabolically diseased animal. In ZDF rats, von Frey thresholds are roughly 80 percent lower than in lean controls from week 4 through week 13, while glucose tolerance and body weight are followed in the same animals. In the streptozotocin model, gabapentin restores withdrawal thresholds to near baseline within a day of dosing, and nerve conduction velocity, evoked potentials and cytokine panels are run in parallel. The same metabolic inductions can be added as a comorbidity arm to other pain models, so that an analgesic candidate is evaluated in the metabolic state characteristic of its patient population.
Metabolic syndrome and wound healing
In the diabetic pig excisional wound model, diabetes is induced with streptozotocin and confirmed by blood glucose. Six full thickness wounds are placed on the pig back so that candidate, comparator and control are evaluated in the same animal against the same systemic background. A non-adherent wound contact layer serves as the standard of care comparator. A hydrogel wound dressing evaluated in this model reached complete closure within 28 days with granulation tissue twice the thickness of the comparator. Aged wound healing runs in the Göttingen minipig. In both models the comorbidity is the defining feature of the design.
Metabolic syndrome and neurodegeneration
Transgenic Alzheimer's mouse lines are run with Morris Water Maze, novel object recognition, amyloid plaque, tau and BDNF endpoints. The 6-OHDA and MPTP Parkinson's models are run with rotarod, cylinder and drug-induced rotation testing and tyrosine hydroxylase histology. Both run in the same facility as the metabolic inductions, and each can include a comorbidity arm designed around the sponsor's population.
Interpretation of Comorbid Study Results
Across these combinations, the metabolic induction is chosen to match the patient population, and the disease model is chosen to match the indication for which the candidate is being developed. The endpoints are measured in the same animals, so that a candidate's effect on glucose handling and its effect on the disease can be evaluated together. A result that is maintained in the comorbid arm is more likely to be reproduced in the clinical population.
MD Biosciences designs comorbidity, age and sex arms around the population a sponsor expects to enroll, across its stroke, pain, wound healing and neurodegeneration models, with a shared platform of behavioral, electrophysiological, histological and biomarker endpoints. Study design conversations are welcome at neuro@mdbiosciences.com.
References:
Abohashem S et al. Trends and Prevalence of the Metabolic Syndrome Among US Adults. JAMA, 2026.
Fisher M et al. Update of the Stroke Therapy Academic Industry Roundtable Preclinical Recommendations. Stroke, 2009.
